Compare Consolidated Edison, Inc. (ED) vs Organon & Co. Common Stock (OGN) Price & Performance

Consolidated Edison (ED) trades at $109.60, up 2.24% with a bullish technical signal. The stock shows strong fundamentals with $16.92B revenue, 12.53% net margin, and consistent dividend payments. Recent earnings show mixed results with Q2 beat but Q1 miss. The company maintains solid cash flow generation of $4.8B from operations in 2025 while investing heavily in infrastructure.

ED presents a stable utility investment with moderate growth and reliable dividends, though analyst consensus leans heavily toward Hold (63%). Key risks include regulatory pressures and capital-intensive infrastructure demands. The current price sits above the $105.56 consensus target, suggesting limited near-term upside despite positive economic impact from New York operations.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.